No effective preventive strategies for cetuximab-induced skin rash are available. In a homogeneous population of 41 consecutive patients with metastatic colorectal cancer, the preventive application of vitamin K 1 ebased cream reduced the development of moderate-to-severe skin rash. Background: Cetuximab is an effective option for the treatment of metastatic colorectal cancer in the first and subsequent lines of treatment; among its side effects, acneiform skin rash is one of the major causes of treatment delay, reduction, or interruption, with a negative effect on quality of life. No effective strategy to prevent skin rash induced by epidermal growth factor receptor inhibitors is available; however, encouraging results have come from vitamin K 1 , phytomenadione, applied as a topical formulation. Available studies have been conducted in heterogeneous populations and are mainly focused on the use of vitamin K 1 ebased cream for the treatment, rather than the prophylaxis, of acneiform rash. Patients and Methods: Forty-one consecutive patients from a single center all affected by metastatic colorectal cancer and receiving cetuximab, alone or combined with chemotherapy, applied vitamin K 1 ebased cream to prevent the occurrence of acneiform skin rash. The cream was applied twice a day on the face and trunk from the first day of administration of cetuximab. Results: The application of the cream was well tolerated. No grade 4 rash was reported. The proportion of grade 3 skin rash in the first 8 weeks of treatment in this population was 15%, at the lower limit of values reported in the literature, and the proportion of patients with grade 2 rash was reduced (22.5%). Conclusion: This experience confirms available data in a homogeneous population, suggesting a possible benefit of topical vitamin K 1 as prophylaxis for cetuximab-induced skin rash in patients with metastatic colorectal cancer.
Introduction
The efficacy of cetuximab (Erbitux) in K-ras wild-type metastatic colorectal cancer (mCRC) is unfortunately associated with a significant risk of skin toxicity, prevalently acneiform skin rash but also xerosis, hair changes, paronychia, nail pitting, nail discoloration, and onycholysis. In fact the majority of patients treated with cetuximab develop an acneiform rash, and it is of severe grade (grade 3 or more) in 10% to 20% of patients (Table 1) . [1] [2] [3] [4] [5] [6] [7] [8] [9] The percentage of moderate (grade 2) rash is not always available in large registration trials; however, in the National Cancer Institute (NCI) CO17 trial, it was reported to be 37.2%.
Incidence and severity of CISR are usually dose-related, although with long-term treatment, rash can decrease. 15 Predictive factors of skin rash are male sex, age younger than 50 years, 16 and colorectal cancer compared with other neoplasms treated with cetuximab. 17 The maintenance of dose intensity through effective skin rash management is fundamental, and there are data indicating a possible association between rash and good prognosis; however, dose-to-rash strategies have not led to improved patient survival. 2, 4, 6, 7, 18, 19 
Treatment of Acneiform Rash
According to recent recommendations by Pinto et al, 20 the treatment of CISR depends primarily on its grade, with an escalation of measures ranging from educational counseling to topical and systemic antibiotics and short courses of steroids. In grade 3 highly symptomatic or nonresponder/grade 4 rash, the treatment must also include retinoids and antihistamines. Cetuximab interruption is necessary in grade 3 CISR and must be followed by dose titration, and after grade 4 rash (eg, interfering with activities of daily living and necessitating intravenous antibiotics), cetuximab must be definitively discontinued. 20 Currently the prophylaxis of skin rash remains controversial. 21 Different strategies to prevent rash have been proposed. [22] [23] [24] Causes of inadequate control of acneiform rash can be the concomitant use of other drugs capable of inducing it, such as immunomodulatory drugs, corticosteroids, neuropsychotherapeutic drugs, and antitubercular drugs. 25 At the same time, the drugs used in the management of CISR, such as topical and systemic corticosteroids and antibiotics, are probably not directed against the real causative pathway of the rash, whose mechanisms are not completely understood. There is, however, evidence of a multiple-factor causative pathway involving both skin inflammation with cetuximab-driven leukocyte chemotaxis and follicular plugging due to skin desquamation and overinfection. A cause of keratinocyte desquamation is epidermal growth factor receptor (EGFR) inhibition in basal keratinocytes that increases the expression of the negative cell-cycle regulator p27, determining cell death. 26 At the same time, a decrease of skin antimicrobial defenses can play an important role, because the EGFR signaling pathway is essential for the induction of expression of Toll-like receptors. 27 Moreover, as an immunoglobulin G1 antibody, cetuximab may exert its antitumor efficacy through both EGFR antagonism and antibody-dependent cell-mediated cytotoxicity; finally, antibodydriven receptor internalization can also be a cause of skin rash. 12 For this reason, the importance of effective mechanism-based therapies is increasing, with the most interesting results coming from vitamin K derivatives. 12, 28 Vitamin K Phytomenadione (vitamin K 1 ) is the major form of dietary vitamin K, and it is metabolized to menaquinones (vitamin K 2 ), the active forms, especially menaquinone 4, through a menadione (vitamin K 3 ) intermediate; menadione is a phosphatase inhibitor. 29 The majority of preclinical data come from menadione (vitamin K 3 ), and clinical data on phytomenadione (vitamin K 1 ) are sparse. Vitamin K 3 is a potent phosphatase inhibitor, and it has been found to be a potent EGFR activator and protector against erlotinib and cetuximab compared with vitamins K 1 and K 2 in malignant and normal keratinocytes in vitro. 30 This effect can be mediated both by reactive oxygen species generation and by phosphatase inhibition at nontoxic concentrations. 31 Other data indicated that menadione reduces erlotinib-induced keratinocyte cytotoxicity more than hydrocortisone, cyclosporine A, minocycline, and diphenhydramine. 32 These studies suggested the rationale for the use of vitamin Kebased preparations in vivo for both treatment and prevention of EGFR-inhibitor-induced skin toxicities. Currently only a few trials are available (Table 2 ).
Patients and Methods
From September 2010 to July 2012, vitamin K 1 ebased cream (Vigorskin) was distributed at San Giovanni Battista Hospital, Turin, Italy, by one of the authors to all patients before starting cetuximab with or without chemotherapy for mCRC. Patients' demographic data, degree of disease extension and occurrence, and degree of CISR, with special attention to the degree of CISR at weeks 4 and 8 of treatment, were then collected. The study was conducted according to the provisions of the Declaration of Helsinki, and all patients gave their informed consent before enrollment. The Vigorskin cream contained 0.1% vitamin K 1 (phytomenadione), urea, Triticum volgare germ oil, hydrolyzed wheat protein, ceramides-1, -3, and -6 II, and phytosphingosine. Before receiving cetuximab, all patients were educated by one of the authors about general measures on how to minimize CISR and how to correctly use Vigorskin cream: limitation of the use of hot water, application of the vitamin K 1 ebased cream twice daily, in the morning and before going to sleep, on the face and trunk after washing/taking a bath and after shaving; avoiding the concomitant application of alcoholic creams or other creams as prophylaxis for CISR. The cream was furnished free from the manufacturer (see Disclosure section), and it was distributed free in 100-mL tubes. Data about cetuximab-induced skin toxicities (rash, xerosis, paronychia, and nail and hair changes) were recorded weekly by one of the investigators, adequately trained for the application of Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 38 ; in doubtful cases, at least 3 investigators met and came to an agreement. CISR was managed according to the protocol recently proposed by Pinto et al. 20 In case of grade 3 skin toxicity, cetuximab was stopped for no more than 21 days, until the CISR improved to grade 2 or less; it was then resumed at full dose. If grade 3 CISR relapsed, the dose was reduced. In case of grade 4 CISR, or grade 3 not improving within 3 weeks, cetuximab was definitively interrupted. In any case, patients were referred to a dermatologist in case of grade 3 or 4 CISR. At the end of treatment with cetuximab, direct telephone interviews with patients were made by one of the investigators; the interviews focused on the ease or burden of applying the cream and on whether the patients interrupted the therapy for more than 1 day or experienced pain or itching after the application.
Results
Forty-one patients undergoing a cetuximab-based regimen for mCRC received vitamin K 1 ebased cream as prophylaxis for CISR. Thirty-four patients received this therapy for at least 12 weeks; 7 patients interrupted within the 12th week: 2 for the execution of radiofrequency thermal ablation, 2 for unacceptable gastroenteric toxicity, 1 for progressive disease, 1 for the occurrence of another neoplasm (follicular lymphoma), and 1 for unacceptable skin toxicity. Only 1 patient had relevant skin comorbidities, namely previous temporal skin zoster. Patients' demographic data, disease extension, drugs associated with cetuximab, and skin comorbidities are summarized in Table 3 .
Globally, 34 patients (82.9%) experienced CISR (of any grade), whereas 6 patients had no rash; in 2 cases, it was not possible to collect data about CISR, because both patients interrupted treatment with cetuximab plus FOLFIRI (fluorouracil/leucovorin/ irinotecan) after only 1 or 2 administrations, owing respectively to unacceptable gastroenteric toxicity and the development of another neoplasm.
Overall, the maximum grade of skin toxicity during the first 8 weeks of treatment, according to CTCAE version 3.0, was grade Second-line therapy, n (%) 16 (39) Single-agent therapy, n (%) 2 (5) þ Irinotecan, n (%) 13 (31.7)
þ Fluoropyrimidine, n (%) 4 (9.8)
þ FOLFIRI/XELIRI, n (%) 16 (39) þ FOLFOX/XELOX, n (%) 6 (14.6) 0, grade 1, grade 2, and grade 3 in, respectively, 6 (15%), 18 (45%), 10 (25%), and 6 (15%) of the patients; no grade 4 CISR has been reported. Overall, 4 patients reported itching, 3 of them having grade 3 skin rash. The mean and median times to the development of the maximum grade of rash were, respectively, 34.7 and 28 days (SD, 24.7). All patients with grade 2 or grade 3 rash were managed with topical or systemic antibiotics. All 6 patients with grade 3 toxicity underwent dermatologist consultation, and the details of their management are reported in Table 4 . Of patients with grade 3 rash, 83% received steroids, 33% received antihistamines, and none received retinoids. In 2 cases, patients requested interruption of the treatment even though the rash recovered within 21 days. All patients were compliant with the application of the cream twice daily on their face and trunk, and no clinically relevant side effects were reported. Only 1 patient reported a sensation of skin burning after applying the cream; this patient, however, applied aftershave lotion despite the contraindication. The median duration of a single 100-mL tube of Vigorskin cream was 10 days.
The incidence of other cetuximab-induced skin toxicities was as follows: skin xerosis, 15% (6 patients); paronychia, 25% (10 patients). These toxicities were all grade 1 or 2 according to CTCAE except in 1 case in which grade 3 paronychia led to a 21-day delay of cetuximab. No other hair or nail toxicities have been reported. Xerosis was not objectionable in the skin areas treated with vitamin K 1 cream. Figures 1 and 2 are photographs of 2 patients experiencing, respectively, grade 3 and grade 2, mainly papular, rash.
Discussion
There is no standard available in the prevention of acneiform rash induced by EGFR inhibitors such as cetuximab. In the population of patients affected by mCRC, a moderate-to-severe acneiform rash occurs in about 50% to 60% of patients, with a dose reduction, in registrative trials, in 4% of patients (see Table 1 ) and a possibly substantial effect on the QoL. [10] [11] [12] [13] [14] To the present authors' knowledge, no effective strategy to prevent EGFR inhibitor-induced skin rash is available. [21] [22] [23] [24] However, encouraging results about a preventive strategy to avoid this distressing adverse effect have come from studies in which vitamin K 1 , phytomenadione, has been applied as a topical formulation (see Table 2 ). Published studies are This study's population was in line with data of common practice: the mean age was 67 years; 61% of patients had a single metastatic site, prevalently the liver; and cetuximab was first-or second-line treatment in nearly 73% of the patients, mainly in association with irinotecan; only 1 patient had a relevant skin comorbidity, namely a previous temporal herpes zoster.
According to the literature, the cream containing 0.01% vitamin K 1 , when applied twice daily as prophylaxis during the whole treatment with cetuximab, seems to reduce the proportion of patients with grade 3 rash to nearly 10% of patients, 37 with a good tolerance as reported from patients 37 and no significant side effect on coagulation. 33 In this study's population, 82.9% of the patients experienced CISR, specifically acneiform inflammatory follicular rash, mainly on the face and trunk, within the first 8 weeks of treatment (see Fig. 2 ). The distribution of the rash was in agreement with the data from the first experience at the authors' institution, 39 and the incidence of grade 3 rash was at the lower limit of what has been reported in the literature (see Table 1 and Table 2 ) and was in agreement with previous data about the prophylactic use of vitamin K 1 ebased cream. 33, 37 Data about the proportion of patients experiencing grade 2 toxicity are scarce in the literature; however, the NCI CO17 trial reported 37.2% grade 2 toxicity 4 ; in the present study, among patients using vitamin K 1 ebased cream as prophylaxis, this rate was reduced to 25%, suggesting a possible benefit of this cream mainly in reducing moderate rash.
In this study's population, grade 2 and 3 rash was managed according to guidelines by Pinto et al, 20 leading to a moderately quick recovery in patients with grade 3 rash (see Table 4 ); 1 patient needed a dose reduction, and in 2 cases patients requested the interruption of the cetuximab. The treatment with vitamin K 1 cream was well tolerated: all patients were compliant with its application twice a day. No patient interrupted the therapy for more than 1 day, and only 1 patient reported skin burning. However, this patient, contrary to previously explained general measures, was also using an aftershave lotion concomitantly.
Conclusion
Globally, this study found a lower proportion of grade 2 rash (25%) and grade 3 rash corresponding to the lower limit reported in the literature on the use of prophylactic vitamin K 1 ebased cream in patients with mCRC treated with cetuximab. The treatment was well tolerated. These data confirm previously published studies suggesting a possible benefit in this population.
Clinical Practice Points
Topical application of vitamin K derivatives seems to be the most promising approach in the prevention of CISR. However, available clinical data are derived from heterogeneous small series. This study reports the largest available series of patients with mCRC treated with vitamin K 1 ebased cream as prophylaxis of CISR. It reports a reduction, compared with historical data, of moderate and severe rash. As found elsewhere in the available literature, the treatment was well tolerated, without any clinically relevant side effects. Vitamin K 1 ebased cream could become a safe topical preventive strategy in patients undergoing cetuximab therapy for mCRC.
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